It’s Not Magic
Psilocybin is of course a Schedule One controlled substance, while amanita is not. As a result, the amanita products are “…often marketed as a dietary supplement…”
Select Page
by C. Scott McMillin | Jul 25, 2024 | Addictive Substances | 0 |
Psilocybin is of course a Schedule One controlled substance, while amanita is not. As a result, the amanita products are “…often marketed as a dietary supplement…”
by C. Scott McMillin | Jul 18, 2024 | Addictive Substances | 0 |
by C. Scott McMillin | May 13, 2024 | Addictive Substances | 0 |
by C. Scott McMillin | Jan 25, 2024 | Addictive Substances | 0 |
by C. Scott McMillin | Jan 11, 2024 | In the News | 0 |
by C. Scott McMillin | Dec 21, 2023 | Addictive Substances | 0 |
by C. Scott McMillin | Nov 27, 2023 | Addictive Substances | 0 |
Translation: the absence of adequate masking would presumably explain why ketamine appeared superior – due to an error in the study design.
Read Moreby C. Scott McMillin | Nov 9, 2023 | Addictive Substances | 0 |
Once again based on experience, I’m confident that many of the folks who will try psilocybin in future, because of all the favorable publicity, will fall into those ‘excluded’ categories.
Read Moreby C. Scott McMillin | Sep 14, 2023 | Addictive Substances | 0 |
All that free positive publicity has surely been a great help to the emerging psychedelic industry and the elements in the financial community who are rushing to exploit it.
Read Moreby C. Scott McMillin | Jul 13, 2023 | Addictive Substances | 0 |
In 1961, two Harvard students ended up in the mental hospital after consuming psilocybin…” Not long afterwards, Harvard lost much of its enthusiasm for the (psilocybin research) program.
Read Moreby C. Scott McMillin | Jun 1, 2023 | Addictive Substances | 0 |
Because studies also suggest some real risks. Dangers, in fact. It’s possible that the current wave of fawning reports of miraculous cures could be replaced by stories of horrific incidents.
Read Moreby C. Scott McMillin | May 22, 2023 | Addictive Substances | 0 |
Antidepressant benefits that are almost immediate but wear off over time. From a patient’s perspective, that could be a real drawback, especially in view of how costly the treatments might have been.
Read Moreby C. Scott McMillin | Apr 24, 2023 | Addictive Substances, In the News | 0 |
When the trip ends, the writer acknowledges, the user may be “…throwing up or having trouble at the other end.”
Read Moreby C. Scott McMillin | Apr 20, 2023 | Addictive Substances, In the News | 0 |
Also, one of the local rags had a few Shroom House products tested and discovered, to no one’s surprise, that some had been made from synthetics. Not the ‘real thing’, after all.
Read Moreby C. Scott McMillin | Mar 6, 2023 | Addictive Substances | 0 |
If 25% of patients in studies either 1) didn’t benefit or 2) had a negative experience, perhaps even a terrifying one– that’s a lot.
Read Moreby C. Scott McMillin | Jan 5, 2023 | Addictive Substances | 0 |
Easy to see how given the right combination of circumstances, it could be wiped out in a relatively short period.
Read Moreby C. Scott McMillin | Dec 5, 2022 | Resources | 0 |
“As we say with most things you come across in a national park, whether it be a banana slug, unfamiliar mushroom, or a large toad with glowing eyes in the dead of night, please refrain from licking…”
Read More